Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 10 µg injection twice daily
LIXI_SC_10UG_BID
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.78 (0.01 to 65.08) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.24 (0.09 to 8.51) | 0.54 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.69 (0.05 to 4.15) | 0.60 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.31 (0.90 to 5.42) | 0.55 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.25 (1.04 to 15.58) | 0.36 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.81 (0.23 to 2.28) | 0.75 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.05 to 15.48) | 0.45 |